Clinical Trial Update: Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. [Phase 2]

View source ↗

Summary

Phase 2 study evaluating two regimens of nivolumab plus ipilimumab in patients with deficient mismatch repair or MSI-high metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Colorectal Cancer with Microsatellite Instability-high

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group | Conditions: Colorectal Cancer Metastatic, MSI-H Colorectal Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING